Living Related Kidney Transplantation Without Calcineurin Inhibitors: Initial Experience in a Mexican Center
- 15 December 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 82 (11), 1533-1536
- https://doi.org/10.1097/01.tp.0000235823.09788.f6
Abstract
We performed a prospective randomized trial comparing sirolimus/mycophenolate mofetil (MMF)/prednisone to cyclosporine/MMF/prednisone and selected induction therapy with basiliximab. Twenty patients received sirolimus (10 mg loading dose followed by 3 mg/m body surface area/day, keeping 24-hr trough levels at 10-15 ng/mL for six months and 5-10 ng/mL thereafter. Twenty-one patients began cyclosporine (4 to 8 mg/kg/day, keeping 12-hour trough levels at 150-300 ng/mL for 6 months and 100-200 ng/mL afterwards). Mean follow up was 15.8 months. One-year patient and graft survival was similar in both groups (>90%). Acute rejection rate was 16.6% in the sirolimus group and 5.2% in the cyclosporine group (P=NS). There were no differences in mean serum creatinine between groups. No patients who received basiliximab and had sirolimus target levels suffered acute rejection at one year. The sirolimus group had significantly higher cholesterol and triglycerides. A calcineurin inhibitor-free regimen using sirolimus produces comparable one-year transplant outcomes in living related kidney transplants compared to a calcineurin inhibitor regimen.Keywords
This publication has 21 references indexed in Scilit:
- Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: A Randomized Trial Comparing Sirolimus and TacrolimusAmerican Journal of Transplantation, 2006
- Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft DysfunctionAmerican Journal of Transplantation, 2004
- Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1Transplantation, 2002
- SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10Transplantation, 2001
- SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12Transplantation, 2000
- Progression of renal damage in chronic rejectionKidney International, 2000
- SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1Transplantation, 1999
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976